NCT04832932View on ClinicalTrials.gov

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2025

Conditions
COVID-19 Vaccines
Interventions
BIOLOGICAL

COVID-19 vaccines

Emergency-use authorized COVID-19 vaccines

Trial Locations (5)

33175

MEBO Research, Inc, Miami

37885

Kahite, Vonore

Unknown

Gabashvili, Tbilisi

8 010

MEBO Research Africa, Kilifi

W10 5LE

Mebo Research (Uk), London

Sponsors

Collaborators (1)

Aurametrix
All Listed Sponsors
collaborator

Aurametrix

OTHER

lead

Mebo Research, Inc.

OTHER

NCT04832932 - The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes | Biotech Hunter | Biotech Hunter